Critical reviews in oncology/hematology
-
Crit. Rev. Oncol. Hematol. · Jul 2015
ReviewMolecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses.
Chordomas, derived from undifferentiated notochordal remnants, represent less than 4% of bone primary tumors. Despite surgery followed by radiotherapy, local and metastatic relapses are frequent. In case of locally advanced or metastatic chordomas, medical treatment is frequently discussed. ⋯ Other putative targets have also been described. Therefore, further clinical trials are expected, especially with these targets. Nevertheless, it seems essential, in those future studies, to consider the naturally slow course of the disease.